Investment Thesis — Cigna Corporation
The market is deeply mispricing Cigna, driven by an extreme and likely technically-induced short interest related to its strategic review or a potential Evernorth spin-off. This creates a rare opportunity to buy a stable healthcare giant at a distressed valuation, poised for a significant re-rating and short squeeze as clarity emerges.
Catalysts
- Clarity and successful execution of the Evernorth strategic review/spin-off
- Strong earnings beats and positive guidance, particularly from the Evernorth segment
- Resolution of extreme short interest leading to a significant short squeeze
Risk Factors
- Increased regulatory pressure on PBMs and managed care organizations
- Failure of strategic initiatives to unlock shareholder value or create operational complexity
- Intensified competition in healthcare services or insurance markets impacting profitability
Key Debates
Cigna's Fwd P/E expands to 10.5x by Q1 2025
Revenue growth accelerates above 4.5% by Q4 2024
Cigna deploys 5%+ of market cap into buybacks by H1 2025